Apoferritin-Cu(II) Nanoparticles Induce Oncosis in Multidrug-Resistant Colon Cancer Cells
© 2023 Wiley-VCH GmbH..
Multidrug resistance (MDR) limits the application of clinical chemotherapeutic drugs. There is an urgent need to develop non-apoptosis-inducing agents that circumvent drug resistance. Herein, four therapeutic copper complexes encapsulated in natural nanocarrier apoferritin (AFt-Cu1-4) are reported. Although they are isomers, they exhibit significantly different organelle distributions and cell death mechanisms. AFt-Cu1 and AFt-Cu3 accumulate in the cytoplasm and induce autophagy, whereas AFt-Cu2 and AFt-Cu4 can quickly enter the nucleus and trigger oncosis. Excitedly, AFt-Cu2 and AFt-Cu4 show a strong tumor growth inhibition effect in mice models bearing multidrug-resistant colon xenograft via intravenous injection. To the best of the authors' knowledge, this is the first example of metal-based nucleus-targeted oncosis inducers overcoming multidrug resistance in vivo.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Advanced healthcare materials - 13(2024), 5 vom: 01. Feb., Seite e2302564 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiong, Kai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
789U1901C5 |
|---|
| Anmerkungen: |
Date Completed 20.02.2024 Date Revised 20.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/adhm.202302564 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365640654 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365640654 | ||
| 003 | DE-627 | ||
| 005 | 20240220232215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/adhm.202302564 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM365640654 | ||
| 035 | |a (NLM)38073257 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xiong, Kai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Apoferritin-Cu(II) Nanoparticles Induce Oncosis in Multidrug-Resistant Colon Cancer Cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.02.2024 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley-VCH GmbH. | ||
| 520 | |a Multidrug resistance (MDR) limits the application of clinical chemotherapeutic drugs. There is an urgent need to develop non-apoptosis-inducing agents that circumvent drug resistance. Herein, four therapeutic copper complexes encapsulated in natural nanocarrier apoferritin (AFt-Cu1-4) are reported. Although they are isomers, they exhibit significantly different organelle distributions and cell death mechanisms. AFt-Cu1 and AFt-Cu3 accumulate in the cytoplasm and induce autophagy, whereas AFt-Cu2 and AFt-Cu4 can quickly enter the nucleus and trigger oncosis. Excitedly, AFt-Cu2 and AFt-Cu4 show a strong tumor growth inhibition effect in mice models bearing multidrug-resistant colon xenograft via intravenous injection. To the best of the authors' knowledge, this is the first example of metal-based nucleus-targeted oncosis inducers overcoming multidrug resistance in vivo | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antitumor | |
| 650 | 4 | |a copper(II) complexes | |
| 650 | 4 | |a metals in medicine | |
| 650 | 4 | |a multidrug-resistance | |
| 650 | 4 | |a oncosis | |
| 650 | 7 | |a Copper |2 NLM | |
| 650 | 7 | |a 789U1901C5 |2 NLM | |
| 650 | 7 | |a Apoferritins |2 NLM | |
| 650 | 7 | |a 9013-31-4 |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Lin, Xinlin |e verfasserin |4 aut | |
| 700 | 1 | |a Kou, Junfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Fangmian |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Jinchao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Liangnian |e verfasserin |4 aut | |
| 700 | 1 | |a Chao, Hui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced healthcare materials |d 2012 |g 13(2024), 5 vom: 01. Feb., Seite e2302564 |w (DE-627)NLM218710070 |x 2192-2659 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:5 |g day:01 |g month:02 |g pages:e2302564 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/adhm.202302564 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 5 |b 01 |c 02 |h e2302564 | ||